Regeneron Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –
Regeneron Pharmaceuticals R&D by Quarter
R&D — Reimbursement of R&D Expenses by Collaborators (Deduction) ($M) ($M)
Regeneron Pharmaceuticals R&D: -$26.5M in Q3 2026, down 19.2% from a year earlier.
Where the Q3 2026 figure comes from
“R&D Expenses Table (FY2026Q3): Reimbursement of research and development expenses by collaborators | (26.5) | (32.8) | 6.3 | (86.4) | (112.5) | 26.1”
Source: Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses Summary Table.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Regeneron Pharmaceuticals R&D ($M), quarterly Q1 2019–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-collab-reimb
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?